biotech
biotech Articles
Gilead Sciences is set to report its most recent quarterly results after the markets close on Tuesday, the first since an announced collaboration with Sangamo Therapeutics.
Published:
Last Updated:
While these four stocks are better suited for accounts that have a higher risk tolerance, they all make good sense now and all have outstanding upside potential.
Published:
Last Updated:
Evelo Biosciences expects to price its more than 5 million shares in a range that results in an initial public offering valued up to almost $104 million.
Published:
Last Updated:
SteadyMed saw its shares skyrocket early on Monday after the company announced that it would be acquired by United Therapeutic.
Published:
Last Updated:
The April 13 short interest data have been compared with the previous report, and short interest in most of the selected biotech stocks increased.
Published:
Last Updated:
Unity Biotechnology plans to offer 5 million shares in an initial public offering valued up to more than $103 million.
Published:
Last Updated:
Epizyme shares tumbled on Tuesday after the FDA announced a partial clinical hold affecting new enrollment of patients in the firm's tazemetostat trials.
Published:
Last Updated:
Creating a treatment for a rare disease or rare disorder can come with massive upside if the treatment is successful. That said, the risk is that a company can implode if its rare disease treatment...
Published:
Last Updated:
Fresenius said Sunday it would terminate its offer to acquire Akorn as the result of the latter's "failure to fulfill several closing conditions."
Published:
Last Updated:
Prothena shares hit a multiyear low on Monday, one that had not been seen since 2013, on the heels of news that the company would be discontinuing development of its treatment for AL amyloidosis.
Published:
Last Updated:
24/7 Wall St. has put together a preview of AbbVie, Eli Lilly and some of the other top pharma and biotech companies reporting their latest quarterly results in the coming week.
Published:
Last Updated:
Ionis Pharmaceuticals shares made a handy gain on Friday after the firm announced an expanded strategic collaboration with Biogen.
Published:
Last Updated:
Calithera Biosciences receives a Fast Track designation for its kidney cancer treatment, sending shares higher.
Published:
Last Updated:
Teligent watched its shares make a solid gain on Wednesday after the firm announced a key approval from the FDA.
Published:
Last Updated:
Rheumatoid arthritis is an autoimmune disease that attacks tissues within the joints, and it is a major target of U.S. and foreign biotechnology and pharmaceutical companies.
Published:
Last Updated: